Forbes October 15, 2024
Amid financial challenges, DNA testing company 23andMe is reportedly exploring a potential sale, which could place the genetic data of over 15 million customers in the hands of new ownership.
The implications of this sale are significant, raising concerns over data privacy and the potential misuse of sensitive genetic information.
What’s at Stake?
23andMe’s genetic database, built over nearly two decades, includes a wealth of information about customers’ health predispositions and ancestral backgrounds.
While the company’s privacy policies claim to prioritize customer consent, a sale could result in a new owner with different priorities.
This change may impact how customers’ DNA data is utilized, potentially opening the door to various uses not initially agreed to by users, including by insurance...
Today's Sponsors
Today's Sponsor